Tweet Surely number one is avoiding..idiot neuro Snider L, Rodriguez E, Rains H, Peraza H, Montalvo M, Rempe T. Factors associated with delays in multiple sclerosis disease-modifying therapy initiation. Mult Scler J Exp Transl Clin. 2026;12:20552173261447996. doi: 10.1177/20552173261447996. PMID: 42112096; PMCID: PMC13153518. Background: In multiple sclerosis…
The post Caring Anyway <span>– Lindsay Kelly</span> appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com
Decode Health and Circular Genomics are partnering to use artificial intelligence (AI) to identify patterns in circular RNA — stable genetic molecules able to signal disease — that may help diagnose multiple sclerosis (MS) earlier and monitor its progression over time. The collaboration brings together…
Ocrevus (ocrelizumab) is an infusion therapy approved to treat adults with relapsing forms of MS and primary progressive MS. Administered via an intravenous infusion, the treatment is used to reduce the frequency of relapses, lower the number of lesions, and slow disability progression. The post…
The U.S. Food and Drug Administration (FDA) has formally agreed that the design and planned analysis of an upcoming Phase 3 trial testing privosegtor in people with optic neuritis could support a future application seeking the therapy’s approval if the trial succeeds. Optic neuritis, or…
Tweet Signori A, Montobbio N, Bovis F, Ponzano M, Schiavetti I, Krenn A, Sormani MP. Uncoupling Relapse Reduction and Disability Progression: Evidence From Tolebrutinib Studies. Neurol Clin Pract. 2026; 16:e200612. Objectives: The aim of this study was to evaluate whether the treatment effects of tolebrutinib on…
If you are living with secondary progressive multiple sclerosis (SPMS), you know that life feels different from how it used to be. For years, you might have lived in the RRMS world, waiting for an attack, treating it, and mostly … Continue reading → Source:…
The U.S. Food and Drug Administration (FDA) has approved the infusion therapy Ocrevus (ocrelizumab) for treating children with relapsing-remitting multiple sclerosis (RRMS) who are ages 10 and older and weigh at least 55 pounds (25 kg). The approval makes Ocrevus the second-ever therapy to win…
I’ve built myself a little quiet life since retiring and going on disability in 2022. It exists on a shoestring with my days spent doing crosswords while listening to music and enjoying various drinks. It’s what I’ve begun to refer to as a still life.…
Tweet As you know I get drawn to studies related to things we have been doing and treatment failure due to anti-drug antibodies is on thing they can also result in faster B cell repopulation. But what other things do we know. Well quite a…